Conference Reports for NATAP

The International Liver Congress™ EASL - European Association for the Study of the Liver Paris France 11-15 April 2018 Back

C-EDGE Treatment Experienced: Effect of 12-Week Oral Regimens of Elbasvir and Grazoprevir on Health Related Quality of Life in Prior Treatment Experienced Patients With Chronic Hepatitis C Infection       Reported by Jules Levin EASL 2018 April 11-15 Paris France   Chizoba Nwankwo1; Daniel Serrano2; Barbara Haber1; Peggy Hwang1; Wenting Li1; Li Lin1; Jean Marie Arduino1 1Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA; 2Pharmerit International, Bethesda, MD, USA   EASL/2015: EFFICACY AND SAFETY OF GRAZOPREVIR/ELBASVIR +/- RBV FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV G1, G4 OR G6 INFECTION WHO PREVIOUSLY FAILED PEGINTERFERON/RBV: C-EDGE TREATMENT-EXPERIENCED - (04/23/15)